Correlation among hyperphosphatemia, type II sodium-phosphate transporter activity, and vitamin D metabolism in Fgf-23 null mice

被引:3
作者
Sitara, Despina [1 ]
机构
[1] Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA
来源
SKELETAL BIOLOGY AND MEDICINE, PT A: ASPECTS OF BONE MORPHOGENESIS AND REMODELING | 2007年 / 1116卷
关键词
Fgf-23; phosphate regulation; vitamin D; bone;
D O I
10.1196/annals.1402.021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Phosphate homeostasisis mostly regulated through humoral factors exerting direct or indirect effects on transporter proteins located in the intestine and kidney. Fibroblast growth factor 23 (FGF-23) is a major phosphate-regulating molecule, which can affect both renal and intestinal phosphate uptake to influence overall mineral ion homeostasis. We have found that Fgf-23 gene knockout mice (Fgf-23(-/-)) develop hyperphosphatemia that consequently leads to abnormal bone mineralization, and severe soft tissue calcifications. On the contrary, FGF-23 transgenic mice develop hypophosphatemia and produce rickets-like features in the mutant bone. Further studies using our Fgf-23(-/-) mice have identified an inverse correlation between Fgf-23, and vitamin D or NaPi2a; genomic elimination of either vitamin D or NaPi2a activities from Fgf-23(-/-) mice could reverse severe hyperphosphatemia to hypophosphatemia, and consequently could alter skeletal mineralization, suggesting that regulation of phosphate homeostasis in Fgf-23(-/-) mice is vitamin D- and NaPi2a-mediated process.
引用
收藏
页码:485 / 493
页数:9
相关论文
共 55 条
[1]  
*ADHR CONS, 2000, ADHR CONS NAT GEN, V26, P345
[2]   MEPE, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone [J].
Argiro, L ;
Desbarats, M ;
Glorieux, FH ;
Ecarot, B .
GENOMICS, 2001, 74 (03) :342-351
[3]   Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders [J].
Bai, XY ;
Miao, DS ;
Li, JR ;
Goltzman, D ;
Karaplis, AC .
ENDOCRINOLOGY, 2004, 145 (11) :5269-5279
[4]   Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities [J].
Beck, L ;
Karaplis, AC ;
Amizuka, N ;
Hewson, AS ;
Ozawa, H ;
Tenenhouse, HS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (09) :5372-5377
[5]   An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia [J].
Benet-Pagès, A ;
Orlik, P ;
Strom, TM ;
Lorenz-Depiereux, B .
HUMAN MOLECULAR GENETICS, 2005, 14 (03) :385-390
[6]   Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent [J].
Berndt, T ;
Craig, TA ;
Bowe, AE ;
Vassiliadis, J ;
Reczek, D ;
Finnegan, R ;
De Beur, SMJ ;
Schiavi, SC ;
Kumar, R .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (05) :785-794
[7]   Biological activity of FGF-23 fragments [J].
Berndt, Theresa J. ;
Craig, Theodore A. ;
McCormick, Daniel J. ;
Lanske, Beate ;
Sitara, Despina ;
Razzaque, Mohammed S. ;
Pragnell, Marlon ;
Bowe, Ann E. ;
O'Brien, Stephen P. ;
Schiavi, Susan C. ;
Kumar, Rajiv .
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2007, 454 (04) :615-623
[8]   Phosphatonins and the regulation of phosphorus homeostasis [J].
Berndt, TJ ;
Schiavi, S ;
Kumar, R .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2005, 289 (06) :F1170-F1182
[9]   Renal phosphate wasting disorders: Clinical features and pathogenesis [J].
Brame, LA ;
White, KE ;
Econs, MJ .
SEMINARS IN NEPHROLOGY, 2004, 24 (01) :39-47
[10]  
Bringhurst FR, 1998, WILLIAMS TXB ENDOCRI, P1155